FGB Gene (Fibrinogen Beta Chain)

Genetic and functional insights into the FGB gene, encoding the beta chain of fibrinogen, a key component in coagulation and hemostasis.

Gene Information Card

Symbol FGB
Full Name Fibrinogen Beta Chain
Gene Type Protein coding
Chromosomal Location 4q31.3
NCBI Gene ID 2244 ncbi.nlm.nih.gov/gene/2244
Ensembl ID ENSG00000171564
UniProt ID P02675
OMIM ID 134830
HGNC ID 3662
Aliases FIBB, fibrinogen B beta chain

Description

The FGB gene encodes the beta chain of fibrinogen, a plasma glycoprotein composed of three pairs of nonidentical polypeptide chains (A-alpha, B-beta, and gamma) linked by disulfide bonds. Fibrinogen is synthesized primarily in the liver and plays a critical role in blood coagulation: upon thrombin cleavage, fibrinogen polymerizes into fibrin, forming a stable clot. Mutations in FGB can lead to quantitative or qualitative fibrinogen disorders, including afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia, which may result in bleeding or thrombotic phenotypes.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Congenital afibrinogenemia Biallelic loss-of-function mutations in FGB leading to absence of functional fibrinogen OMIM #202400; ClinVar
Hypofibrinogenemia Heterozygous or compound heterozygous mutations reducing fibrinogen levels OMIM #134830; NCBI Gene
Dysfibrinogenemia Missense mutations altering fibrinogen structure and function, impairing polymerization or thrombin binding OMIM #134830; ClinVar
Thrombosis (venous/arterial) Certain FGB variants (e.g., -455G>A promoter polymorphism) associated with elevated fibrinogen levels and increased thrombotic risk NCBI Gene; PubMed

Expression Profile

Tissue Expression
Tissue nTPM level
Liver 112.1 High
Blood 0.5 Low
Bone marrow 0.3 Low
Other tissues <0.1 Not detected
Cell Line Expression
Cell Line nTPM Notes
HepG2 98.5 Hepatocellular carcinoma cell line; high expression
Huh-7 85.2 Hepatoma cell line
K-562 0.2 Chronic myeloid leukemia; low expression
HeLa 0.1 Cervical carcinoma; negligible
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.124G>A (p.Gly42Ser) Missense Rare Dysfibrinogenemia; impaired fibrin polymerization
c.103C>T (p.Arg35Ter) Nonsense Rare Afibrinogenemia; premature stop codon, loss of function
c.1129G>A (p.Gly377Ser) Missense Rare Hypofibrinogenemia; reduced secretion
c.147+1G>T Splice site Rare Afibrinogenemia; aberrant splicing, null allele
Mutation functional classification

Loss of Function (LOF)

Nonsense, frameshift, and splice-site mutations leading to afibrinogenemia or hypofibrinogenemia (e.g., p.Arg35Ter, c.147+1G>T).

Gain of Function (GOF)

Not reported for FGB; gain-of-function variants are not characteristic of this gene.

Dominant Negative (DN)

Missense mutations causing dysfibrinogenemia (e.g., p.Gly42Ser) can exert dominant-negative effects by incorporating mutant chains into fibrinogen, impairing polymerization.

Pathways

KEGG hsa04610 – Complement and coagulation cascades
Reactome R-HSA-140877 – Formation of Fibrin Clot (Clotting Cascade)
Reactome R-HSA-76002 – Platelet activation
signaling and aggregation

Protein Summary

Fibrinogen beta chain (UniProt P02675) is a 491-amino acid protein that forms the B-beta subunit of fibrinogen. It is synthesized in the liver and secreted into plasma. The beta chain contains a coiled-coil domain and a C-terminal globular domain involved in fibrin polymerization. Post-translational modifications include N-glycosylation and disulfide bond formation. The protein is essential for clot formation; defects lead to bleeding or thrombotic disorders.

Related Products

Product name Cat.No. Species Gene ID
FGB Knockout HEK293 Cell Line EDJ-KQ2950 Human 2244 Details Get a Quote
FGB Knockout A-549 Cell Line EDJ-KQ22713 Human 2244 Details Get a Quote
FGB Knockout HeLa Cell Line EDJ-KQ53219 Human 2244 Details Get a Quote
FGB Knockout HCT 116 Cell Line EDJ-KQ70185 Human 2244 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: